We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Terlipressin Administration in Septic Shock Refractory to Catecholamines

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2008 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00793559
First Posted: November 19, 2008
Last Update Posted: November 19, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Assaf-Harofeh Medical Center
November 18, 2008
November 19, 2008
November 19, 2008
November 2008
July 2009   (Final data collection date for primary outcome measure)
CI, SVR,HR,BP, noradrenalin administration,renal function [ Time Frame: 6 mo ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Terlipressin Administration in Septic Shock Refractory to Catecholamines
Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II
terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Septic Shock
  • Drug: terlipressin
    1 mg of terlipressin one time only
    Other Name: glypressin
  • Drug: terlipressin
    1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
  • Active Comparator: terlipressin bolus
    1 mg of terlipressin received one time only
    Intervention: Drug: terlipressin
  • Experimental: terlipressin drip
    Intervention: Drug: terlipressin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
30
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • septic shock patients receiving above 0.5 mcg/kg NA

Exclusion Criteria:

  • allergy to terlipressin, CHF, IHD, pregnancy
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00793559
161/08
No
Not Provided
Not Provided
Dr Yuval Leonov, Assaf-Harofeh Medical Center
Assaf-Harofeh Medical Center
Not Provided
Study Director: Tal Mann, Dr Asaf Harofeh
Assaf-Harofeh Medical Center
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP